FORMACIÓN CONTINUADA - ACTUALIZACIÓN EN MEDICINA DE FAMILIA Análogos de insulina: modificaciones en la estructura, consecuencias moleculares y metabólicas

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin Aspart

  2012cited by this paper
• Growth hormone, the insulin-like growth factor axis, insulin and cancer risk

  2011cited by this paper
• Treatment with insulin detemir or NPH insulin in children aged 2–5 yr with type 1 diabetes mellitus

  2011cited by this paper
• Diabetes and Cancer

  2010cited by this paper
• In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

  2010cited by this paper
• Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

  2009cited by this paper
• Combined randomised controlled trial experience of malignancies in studies using insulin glargine

  2009cited by this paper
• The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

  2009cited by this paper
• Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

  2009cited by this paper
• Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

  2009cited by this paper
• Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

  2009cited by this paper
• No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

  2009cited by this paper
• Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

  2009cited by this paper
• Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy

  2007cited by this paper
• Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal–bolus scheme with NPH insulin in a 12‐wk crossover study of preschool children with type 1 diabetes

  2007cited by this paper
• A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

  2005cited by this paper
• Insulin Detemir—A New Basal Insulin Analog

  2005cited by this paper
• Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.

  2004cited by this paper
• Las nuevas insulinas: Revisión

  2004cited by this paper
• Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

  2004cited by this paper
• Effects of Rapid-Acting Insulin Analogs on Overall Glycemic Control in Type 1 and Type 2 Diabetes Mellitus

  2003cited by this paper
• [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action.

  2003cited by this paper
• A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1.

  2003cited by this paper
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003cited by this paper
• Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.

  2003cited by this paper
• Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.

  2001cited by this paper
• Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

  2000cited by this paper
• Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

  2000cited by this paper
• Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.

  2000cited by this paper
• Insulin aspart: a novel rapid-acting human insulin analogue.

  1999cited by this paper
• Insulin analogues and their potential in the management of diabetes mellitus

  1999cited by this paper
• Optimal Time of Administration of Insulin Lispro. Importance of meal composition

  1998cited by this paper
• Insulin Lispro in CSII: Results of a Double-Blind Crossover Study

  1997cited by this paper
• Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDM

  1996cited by this paper
• Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin

  1996cited by this paper
• Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin

  1996cited by this paper
• Pre‐meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 Diabetes

  1996cited by this paper
• Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM

  1994cited by this paper

• Reduced sexual motivation of diabetic female rats: Restoration with insulin.

  2021cites this paper
• Reduced Lordosis and Enhanced Aggression in Paced and Non-Paced Mating in Diabetic Female Rats.

  2017cites this paper